CHRNB4

Summary

CHRNB4 (cholinergic receptor nicotinic beta 4 subunit, HGNC:1964) is a protein-coding gene on chromosome 15q25.1, encoding Neuronal acetylcholine receptor subunit beta-4 (P30926). Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate syna….

This gene is found within a conserved gene cluster and encodes one of the beta subunits of the nicotinic acetylcholine receptor (nAChRs) superfamily which form ligand-gated ion channels with a central pore that forms a cation channel. Neuronal nAChRs are pentameric structures that can be either homomeric or heteromeric, with heteromeric structures containing both alpha and beta subunits. Each subunit contains an extracellular amino terminus and four transmembrane domains. Nicotine is one of the agonists that binds to the receptor. Variants in this gene have been associated with nicotine dependence and lung cancer. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 1143 — RefSeq curated summary.

At a glance

• Gene–disease (curated): lung cancer (Limited, GenCC)
• GWAS associations: 65
• Clinical variants (ClinVar): 67 total — 1 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 1
• Druggable target: yes — 20 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000750

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1964
Approved symbol	CHRNB4
Name	cholinergic receptor nicotinic beta 4 subunit
Location	15q25.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000117971
Ensembl biotype	protein_coding
OMIM	118509
Entrez	1143

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000261751, ENST00000412074, ENST00000558216, ENST00000559849, ENST00000560511, ENST00000560868, ENST00000929174, ENST00000929175

RefSeq mRNA: 2 — MANE Select: NM_000750 NM_000750, NM_001256567

CCDS: CCDS10306, CCDS58392

Canonical transcript exons

ENST00000261751 — 6 exons

Exon	Start	End
ENSE00000794044	78631076	78631185
ENSE00001262649	78628967	78629945
ENSE00001664559	78624111	78625291
ENSE00003695137	78635439	78635587
ENSE00003701007	78631288	78631332
ENSE00003843453	78641079	78641210

Expression profiles

Bgee: expression breadth ubiquitous, 125 present calls, max score 82.37.

FANTOM5 (CAGE): breadth broad, TPM avg 0.6693 / max 115.2605, expressed in 209 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
151124	0.3839	142
151123	0.2621	105
151125	0.0233	3

Top tissues by expression

232 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.37	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.21	gold quality
right testis	UBERON:0004534	77.82	gold quality
left testis	UBERON:0004533	77.69	gold quality
testis	UBERON:0000473	75.27	gold quality
buccal mucosa cell	CL:0002336	74.67	silver quality
adrenal tissue	UBERON:0018303	73.03	gold quality
ganglionic eminence	UBERON:0004023	71.36	gold quality
cortical plate	UBERON:0005343	66.58	gold quality
muscle layer of sigmoid colon	UBERON:0035805	60.81	gold quality
ventricular zone	UBERON:0003053	58.67	gold quality
sural nerve	UBERON:0015488	58.33	silver quality
right adrenal gland	UBERON:0001233	57.67	gold quality
adrenal gland	UBERON:0002369	57.61	gold quality
vermiform appendix	UBERON:0001154	57.37	gold quality
tendon of biceps brachii	UBERON:0008188	57.25	gold quality
sigmoid colon	UBERON:0001159	57.03	gold quality
left adrenal gland cortex	UBERON:0035825	56.52	gold quality
metanephric glomerulus	UBERON:0004736	55.97	gold quality
left adrenal gland	UBERON:0001234	55.62	gold quality
adrenal cortex	UBERON:0001235	54.98	gold quality
lower esophagus mucosa	UBERON:0035834	54.95	gold quality
right adrenal gland cortex	UBERON:0035827	54.51	gold quality
esophagus mucosa	UBERON:0002469	54.45	gold quality
caecum	UBERON:0001153	53.58	gold quality
thymus	UBERON:0002370	53.58	silver quality
colon	UBERON:0001155	52.34	gold quality
lymph node	UBERON:0000029	52.18	gold quality
large intestine	UBERON:0000059	51.92	gold quality
colonic epithelium	UBERON:0000397	51.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.21

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ASCL1, SOX10, SP1, SP3

miRNA regulators (miRDB)

41 targeting CHRNB4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-1295B-5P	99.03	67.50	810

Literature-anchored findings (GeneRIF, showing 40)

• CHRNB4 subunit is expressed in the soma of the majority of pyramidal cells, with fairly consistent immunoreactivity observed throughout the different regions of the hippocampus. (PMID:12663058)
• absence of differences in the pharmacological profile of nicotinic receptor alpha3beta4 argues against role for incorporated beta3 subunit in formation of agonist binding sites while changes in channel kinetics suggest important effect on receptor gating (PMID:12912995)
• The receptors containing the R136W and M467V mutations (or variants) had a higher sensitivity to acetylcholine and lower EC50 than the wild-type. (PMID:15742216)
• In the 2,827 long-term smokers examined, common susceptibility and protective haplotypes at the CHRNA5-A3-B4 locus were associated with nicotine dependence severity. (PMID:18618000)
• Correlated SNPs in the cholinergic nicotinic receptor gene cluster CHRNA5-CHRNA3-CHRNB4, in a case-control study of cocaine dependence composed of 504 European-American and 583 African-Americans. (PMID:18759969)
• CHRNB4 seem to exert no relevant influence on smoking cessation probability in heavy smokers in the general population. (PMID:18996504)
• Two distinct variant groups in the CHRNA5-CHRNA3-CHRNB4 gene cluster are strongly associated with heavy smoking. The snp rs16969968 alters the coding sequence of these genes. (PMID:19029397)
• Genetic variant in the CHRNA5-CHRNA3-CHRNB4 gene cluster is associated with smoking cessation during pregnancy. (PMID:19429911)
• Missense mutation of CHRNB4, CHRNB3 and CHRNA4 are associated with sporadic amyotrophic lateral sclerosis. (PMID:19628475)
• Genetic variation at CHRNA5/CHRNA3/CHRNB4 cluster influences blood nicotine level. (PMID:19628476)
• These results indicate that variants within CHRNA3 and among CHRNA5, CHRNA3, and CHRNB4 contribute significantly to the etiology of ND through gene-gene interactions. (PMID:19859904)
• Data suggest that interactions between alpha3beta4 nAChRs and P2X2 receptors may modulate transmission at enteric synapses that use ATP and acetylcholine as co-transmitters. (PMID:20426799)
• The data of this study supported the importance of variants in the CHRNA5/A3/B4 gene cluster as mediators of the genetic risk for substance dependence. (PMID:20485328)
• Variation in the nicotinic acetylcholine receptor gene cluster CHRNA5-CHRNA3-CHRNB4 influences cognitive flexibility differently in African Americans and European Americans. (PMID:20631687)
• This review focuses on the clustered nicotinic acetylcholine receptor genes CHRNalpha5/alpha3/beta4 and evaluates their role in nicotine addiction and lung cancer. (PMID:20685379)
• associations of variants in the CHRNA5/A3/B4 cluster with smoking initiation, smoking quantity and smoking cessation (PMID:20808433)
• evidence that CHRNA5-CHRNA3-CHRNB4 gene cluster variants,particularly CHRNA5 variant rs16969968, could be associated with cognitive performance possibly mediating in part risk for developing nicotine dependence (PMID:20886544)
• functional properties of nAChRs containing beta4R349C subunit; mutation caused reduction in potency of ACh and nicotine, decreased density of whole-cell current evoked by maximal transmitter concentrations, altered kinetics of ACh-evoked whole-cell currents (PMID:21107856)
• CHRNA5-CHRNA3-CHRNB4 is involved in the transition toward heavy smoking in mid-adulthood and in smoking persistence. (PMID:21168125)
• Single nucleotide polymorphism (SNP) CHRNB4 on chromosome 15 is not associated with Parkinson’s disease risk in the overall anaylsis or after stratifying on smoking status. (PMID:21228559)
• Variant A of the rs1051730 SNP of CHRNA5-A3-B4 gene cluster was significantly associated with smoking quantity in 2 Italian populations, Val Borbera and Cilento, no association was found in Carlantino population. (PMID:21248747)
• neuronal nicotinic acetylcholine receptors alpha4beta4 and alpha7 show differential agonist binding modes (PMID:21343288)
• Single Nucleotide Polymorphisms in CHRNB4 is associated with smoking persistence in African Americans. (PMID:21436384)
• The A2A receptor reduces the desensitization of alpha3beta4 nAChR through the action of protein kinase A. Mutations disrupting the sequence 385RAES388 abolish PKA-induced changes in nAChR function. (PMID:21486776)
• Nicotinic acetylcholine receptor polymorphisms are associated with additional increased risk of lung cancer, bladder cancer, and chronic obstructive pulmonary disease after adjustment for smoking. (PMID:21646606)
• Variation in CHRNA5-A3-B4 was independently and additively associated with increased smoking, nicotine dependence, and lung cancer risk. (PMID:21747048)
• alpha6beta4* nAChRs are expressed and contribute to exocytosis in human chromaffin cells of the adrenal gland, the main source of adrenaline under stressful situations. (PMID:21917987)
• Overexpression of alpha3/alpha5/beta4 nicotinic acetylcholine receptor subunits produces changes in two specific aspects of executive functioning–working memory and response inhibition–that may be related to nicotine dependence vulnerability. (PMID:22024278)
• This study examines whether the CHRNA5/CHRNA3/CHRNB4 locus is correlated also with externalizing behaviors in three independent longitudinally assessed adolescent samples (PMID:22042234)
• Missense variants at conserved residues in CHRNB4 are associated with lower risk for nicotine dependence in African Americans and European Americans. (PMID:22042774)
• vivo evidence of the involvement of the CHRNA5, CHRNA3 and CHRNB4 genomic cluster in nicotine addiction (PMID:22101982)
• Single nucleotide polymorphisma in CHRNB4 showed suggestive association with the comorbidity of depression and nicotine dependence. (PMID:22241830)
• The genetic risks of nicotine dependence associated with the CHRNA5-A3-B4 subunit genes are specific, and not shared among commonly comorbid psychiatric disorders (PMID:22336398)
• Collectively, the presence of alpha7 and beta4 nAChRs in PDLSCs supports a key role of Nicotinic acetylcholine receptor (nAChRs) in the modulation of nicotine-induced apoptosis (PMID:22382680)
• study provides evidence for a general role of the CHRNA5/A3/B4 gene cluster in substance use initiation that is not limited to nicotine and alcohol. (PMID:22382757)
• Quantitative trait disequilibrium test (QTDT) significant association was detected between age at onset of daily smoking and variants located upstream of CHRNB4. (PMID:22438940)
• transgenic mice with human alpha 5, alpha 3, beta 4 subunit genes drank less ethanol than wild-type in a two-bottle (ethanol vs. water) preference test; results suggest a complex role for this receptor subunit gene cluster in the modulation of ethanol’s as well as nicotine’s effects (PMID:22459873)
• Compared with etomidate, carboetomidate’s higher hydrophobicity is associated with greater inhibition of alpha4/beta2 neuronal nicotinic acetylcholine receptors. (PMID:22543065)
• epigenetic deregulation of nicotinic acetylcholine receptor subunit (nAChR) genes which in the case of CHRNB4 is strongly associated with genetic lung cancer susceptibility variants and a functional impact on tumorigenic potential (PMID:22945651)
• Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence birth weight. (PMID:22956269)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	chrnb4	ENSDARG00000101677
mus_musculus	Chrnb4	ENSMUSG00000035200
rattus_norvegicus	Chrnb4	ENSRNOG00000014427

Paralogs (45): GABRA3 (ENSG00000011677), GABRA1 (ENSG00000022355), CHRNA3 (ENSG00000080644), GABRP (ENSG00000094755), CHRNA4 (ENSG00000101204), GLRA2 (ENSG00000101958), GABRE (ENSG00000102287), CHRNE (ENSG00000108556), GABRA4 (ENSG00000109158), GLRB (ENSG00000109738), GABRR2 (ENSG00000111886), GABRG2 (ENSG00000113327), CHRNA2 (ENSG00000120903), CHRNA10 (ENSG00000129749), CHRND (ENSG00000135902), CHRNA1 (ENSG00000138435), GLRA3 (ENSG00000145451), GABRA6 (ENSG00000145863), GABRB2 (ENSG00000145864), GLRA1 (ENSG00000145888), GABRR1 (ENSG00000146276), CHRNB3 (ENSG00000147432), CHRNA6 (ENSG00000147434), HTR3B (ENSG00000149305), GABRA2 (ENSG00000151834), CHRNB2 (ENSG00000160716), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRB3 (ENSG00000166206), CHRFAM7A (ENSG00000166664), HTR3A (ENSG00000166736), CHRNA5 (ENSG00000169684), CHRNB1 (ENSG00000170175), CHRNA9 (ENSG00000174343), CHRNA7 (ENSG00000175344), HTR3C (ENSG00000178084), GABRG3 (ENSG00000182256), GABRR3 (ENSG00000183185), HTR3E (ENSG00000186038), HTR3D (ENSG00000186090)

Protein

Protein identifiers

Neuronal acetylcholine receptor subunit beta-4 — P30926 (reviewed: P30926)

All UniProt accessions (2): P30926, H3BU02

UniProt curated annotations — full annotation on UniProt →

Function. Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators. CHRNB4 forms heteropentameric neuronal acetylcholine receptors with CHRNA2, CHRNA3 and CHRNA4, as well as CHRNA5 and CHRNB3 as accesory subunits. CHRNA3:CHRNB4 being predominant in neurons of the autonomic ganglia, it is known as ganglionic nicotinic receptor. CHRNA3:CHRNB4 or CHRNA3:CHRNA5:CHRNB4 play also an important role in the habenulo-interpeduncular tract, modulating the mesolimbic dopamine system and affecting reward circuits and addiction. Hypothalamic CHRNA3:CHRNB4 nAChR activation by nicotine leads to activation of POMC neurons and a decrease in food intake.

Subunit / interactions. Neuronal AChR is composed of two different types of subunits: alpha and beta. CHRNB4/Beta-4 subunit can be combined to CHRNA2/alpha-2, CHRNA3/alpha-3 or CHRNA4/alpha-4, CHRNA5/alpha-5 and CHRNB3/beta-3 to give rise to functional receptors. Forms stoichiometries such as (CHRNA3)2:(CHRNB4)3 or (CHRNA3:CHRNB4)2:CHRNB3. Interacts with RIC3; which is required for proper folding and assembly. Interacts with LYPD6.

Subcellular location. Synaptic cell membrane. Cell membrane.

Activity regulation. Activated by a myriad of ligands such as acetylcholine, cytisine, nicotine, choline and epibatidine. The heteropentamer CHRNA3:CHRNB4 activity is blocked by the alpha-conotoxin ImI and AuIB.

Similarity. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta-4/CHRNB4 sub-subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P30926-1	1	yes
P30926-2	2

RefSeq proteins (2): NP_000741, NP_001243496 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002394	Nicotinic_acetylcholine_rcpt	Family
IPR006029	Neurotrans-gated_channel_TM	Domain
IPR006201	Neur_channel	Family
IPR006202	Neur_chan_lig-bd	Domain
IPR018000	Neurotransmitter_ion_chnl_CS	Conserved_site
IPR036719	Neuro-gated_channel_TM_sf	Homologous_superfamily
IPR036734	Neur_chan_lig-bd_sf	Homologous_superfamily
IPR038050	Neuro_actylchol_rec	Homologous_superfamily

Pfam: PF02931, PF02932

Catalyzed reactions (Rhea), 3 shown:

• K(+)(in) = K(+)(out) (RHEA:29463)
• Ca(2+)(in) = Ca(2+)(out) (RHEA:29671)
• Na(+)(in) = Na(+)(out) (RHEA:34963)

UniProt features (59 total): strand 15, helix 8, turn 7, topological domain 5, glycosylation site 4, sequence variant 4, transmembrane region 4, site 2, splice variant 2, sequence conflict 2, signal peptide 1, chain 1, region of interest 1, binding site 1, disulfide bond 1, mutagenesis site 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
8ZRN	ELECTRON MICROSCOPY	3.25
8ZRP	ELECTRON MICROSCOPY	3.32
6PV7	ELECTRON MICROSCOPY	3.34
6PV8	ELECTRON MICROSCOPY	3.87

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30926-F1	82.08	0.62

Antibody-complex structures (SAbDab): 2 — 6PV7, 6PV8

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 82 (key residue that facilitates effective access of the conotoxin buia to the channel binding site); 134 (key residue for a low dissociation (k(off)) from the conotoxin buia)

Ligand- & substrate-binding residues (1): 262

Disulfide bonds (1): 153–167

Glycosylation sites (4): 36, 93, 138, 166

Mutagenesis-validated functional residues (1):

Position	Phenotype
272	increases potency of agonists.

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-629587	Highly sodium permeable postsynaptic acetylcholine nicotinic receptors
R-HSA-629594	Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
R-HSA-629597	Highly calcium permeable nicotinic acetylcholine receptors
R-HSA-6798695	Neutrophil degranulation
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission
R-HSA-112315	Transmission across Chemical Synapses
R-HSA-112316	Neuronal System
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-181431	Acetylcholine binding and downstream events
R-HSA-622323	Presynaptic nicotinic acetylcholine receptors
R-HSA-622327	Postsynaptic nicotinic acetylcholine receptors

MSigDB gene sets: 196 (showing top): GOBP_EXCRETION, MODULE_92, GOBP_MEMBRANE_DEPOLARIZATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_INNATE_IMMUNE_SYSTEM, MODULE_274, GOBP_BEHAVIOR, GOCC_SECRETORY_GRANULE, GOBP_ADULT_BEHAVIOR, MODULE_64, GOBP_SYNAPTIC_TRANSMISSION_CHOLINERGIC, GOBP_REGULATION_OF_SMOOTH_MUSCLE_CONTRACTION, GOBP_NEUROTRANSMITTER_TRANSPORT, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, MORF_RAD51L3

GO Biological Process (18): monoatomic ion transport (GO:0006811), smooth muscle contraction (GO:0006939), regulation of smooth muscle contraction (GO:0006940), signal transduction (GO:0007165), synaptic transmission, cholinergic (GO:0007271), locomotory behavior (GO:0007626), neuronal action potential (GO:0019228), monoatomic ion transmembrane transport (GO:0034220), behavioral response to nicotine (GO:0035095), regulation of neurotransmitter secretion (GO:0046928), membrane depolarization (GO:0051899), positive regulation of transmission of nerve impulse (GO:0051971), synaptic transmission involved in micturition (GO:0060084), acetylcholine receptor signaling pathway (GO:0095500), response to nicotine (GO:0035094), regulation of membrane potential (GO:0042391), regulation of postsynaptic membrane potential (GO:0060078), excitatory postsynaptic potential (GO:0060079)

GO Molecular Function (8): ligand-gated monoatomic ion channel activity (GO:0015276), acetylcholine receptor activity (GO:0015464), acetylcholine-gated monoatomic cation-selective channel activity (GO:0022848), transmembrane signaling receptor activity (GO:0004888), monoatomic ion channel activity (GO:0005216), extracellular ligand-gated monoatomic ion channel activity (GO:0005230), protein binding (GO:0005515), transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential (GO:1904315)

GO Cellular Component (13): plasma membrane (GO:0005886), acetylcholine-gated channel complex (GO:0005892), membrane (GO:0016020), specific granule membrane (GO:0035579), neuron projection (GO:0043005), synapse (GO:0045202), tertiary granule membrane (GO:0070821), neurotransmitter receptor complex (GO:0098878), cholinergic synapse (GO:0098981), postsynaptic specialization membrane (GO:0099634), cation channel complex (GO:0034703), postsynaptic membrane (GO:0045211), synaptic membrane (GO:0097060)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Presynaptic nicotinic acetylcholine receptors	2
Postsynaptic nicotinic acetylcholine receptors	2
Acetylcholine binding and downstream events	2
Innate Immune System	1
Transmission across Chemical Synapses	1
Neuronal System	1
Immune System	1
Neurotransmitter receptors and postsynaptic signal transmission	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transmission of nerve impulse	2
regulation of membrane potential	2
regulation of postsynaptic membrane potential	2
postsynaptic neurotransmitter receptor activity	2
monoatomic ion channel complex	2
plasma membrane signaling receptor complex	2
secretory granule membrane	2
synapse	2
synaptic membrane	2
transport	1
muscle contraction	1
regulation of muscle contraction	1
smooth muscle contraction	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
chemical synaptic transmission	1
behavior	1
action potential	1
monoatomic ion transport	1
transmembrane transport	1
adult behavior	1
response to nicotine	1
neurotransmitter secretion	1
modulation of chemical synaptic transmission	1
regulation of neurotransmitter transport	1
regulation of secretion by cell	1
positive regulation of cell communication	1
positive regulation of nervous system process	1
regulation of transmission of nerve impulse	1
neuromuscular synaptic transmission	1
micturition	1
acetylcholine receptor activity	1
postsynaptic signal transduction	1
cellular response to acetylcholine	1
response to chemical	1
monoatomic ion transmembrane transport	1
regulation of biological quality	1

Protein interactions and networks

STRING

816 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CHRNB4	PSMA4	P25789	938
CHRNB4	CHRNA3	P32297	822
CHRNB4	RIC3	Q7Z5B4	755
CHRNB4	HYKK	A2RU49	700
CHRNB4	DEGS2	Q6QHC5	608
CHRNB4	IGBP1	P78318	606
CHRNB4	CYP2A6	P00190	603
CHRNB4	IREB2	P48200	577
CHRNB4	GABBR2	O75899	568
CHRNB4	NMUR2	Q9GZQ4	559
CHRNB4	SLC6A4	P31645	557
CHRNB4	CHRM2	P08172	557
CHRNB4	SLC17A6	Q9P2U8	538
CHRNB4	DRD1	P21728	526
CHRNB4	HTR2A	P28223	514

IntAct

9 interactions, top by confidence:

A	B	Type	Score
CHRNB4	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
LYPD6	CHRNB2	psi-mi:“MI:0914”(association)	0.350
LYNX1	CHRNB2	psi-mi:“MI:0914”(association)	0.350
HCN1	USP27X	psi-mi:“MI:0914”(association)	0.350
CHRNB4	GPR89A	psi-mi:“MI:0914”(association)	0.350
CHRNB4	MEOX2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (69): CHRNB4 (Affinity Capture-RNA), CHRNB4 (Affinity Capture-MS), CHRNB4 (Two-hybrid), CHRNB4 (Affinity Capture-MS), SQSTM1 (Affinity Capture-MS), ABHD14A (Affinity Capture-MS), RHBDD3 (Affinity Capture-MS), UBA52 (Affinity Capture-MS), BNIP1 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), ANO6 (Affinity Capture-MS), RNF215 (Affinity Capture-MS), SPPL2B (Affinity Capture-MS), DNAJB9 (Affinity Capture-MS), PLD6 (Affinity Capture-MS)

ESM2 similar proteins: A8WQK3, O16926, P02708, P02709, P02710, P02711, P02712, P02718, P04755, P04756, P04757, P05377, P09478, P09479, P09481, P09484, P09628, P12389, P12392, P17644, P18845, P19370, P20420, P22456, P23414, P25108, P25162, P26152, P26153, P30926, P32297, P43143, P48180, P48181, P49579, P49581, P91766, Q07263, Q15825, Q23022

Diamond homologs: A8WQK3, O16926, O70174, P02708, P02709, P02710, P02711, P02712, P02713, P02716, P02717, P04755, P04756, P04757, P04758, P04759, P05377, P09478, P09479, P09480, P09481, P09482, P09483, P09484, P09628, P09690, P11230, P12389, P12390, P12391, P12392, P13908, P17644, P17787, P18257, P18845, P19370, P20420, P22456, P22770

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CHRNB4	“form complex”	“Neuronal nicotinic acetylcholine receptor complex, alpha3-alpha5-beta4”	binding
CHRNB4	“form complex”	“Neuronal nicotinic acetylcholine receptor complex, alpha3-alpha6-beta4”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	43
Likely benign	8
Benign	8

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
3336651	NM_000750.5(CHRNB4):c.1411G>C (p.Val471Leu)	Pathogenic
1344512	NM_000750.5(CHRNB4):c.178C>T (p.Leu60Phe)	Likely pathogenic
1344513	NM_000750.5(CHRNB4):c.658G>A (p.Val220Met)	Likely pathogenic

SpliceAI

1209 predictions. Top by Δscore:

Variant	Effect	Δscore
15:78628374:T:TA	donor_gain	1.0000
15:78628375:C:A	donor_gain	1.0000
15:78628965:A:AC	donor_gain	1.0000
15:78628966:C:CC	donor_gain	1.0000
15:78628966:CA:C	donor_gain	1.0000
15:78628966:CACT:C	donor_gain	1.0000
15:78629957:C:CT	acceptor_gain	1.0000
15:78631070:ACTCA:A	donor_loss	1.0000
15:78631073:CA:C	donor_loss	1.0000
15:78631074:A:AC	donor_gain	1.0000
15:78631075:C:CC	donor_gain	1.0000
15:78631075:CTT:C	donor_gain	1.0000
15:78631075:CTTG:C	donor_gain	1.0000
15:78631181:CATTC:C	acceptor_gain	1.0000
15:78631183:TTC:T	acceptor_gain	1.0000
15:78631184:TC:T	acceptor_gain	1.0000
15:78631185:CC:C	acceptor_gain	1.0000
15:78631185:CCTGG:C	acceptor_loss	1.0000
15:78631186:C:CC	acceptor_gain	1.0000
15:78631186:CTGG:C	acceptor_loss	1.0000
15:78631187:T:A	acceptor_loss	1.0000
15:78635438:CCACG:C	donor_gain	1.0000
15:78628356:AAAG:A	donor_gain	0.9900
15:78628959:CAACT:C	donor_loss	0.9900
15:78628960:AACTT:A	donor_loss	0.9900
15:78628961:ACTTA:A	donor_loss	0.9900
15:78628962:CTTAC:C	donor_loss	0.9900
15:78628963:TT:T	donor_loss	0.9900
15:78628964:TACA:T	donor_loss	0.9900
15:78628965:A:C	donor_loss	0.9900

AlphaMissense

3279 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:78629702:C:A	W201C	0.999
15:78629702:C:G	W201C	0.999
15:78631104:A:G	W111R	0.999
15:78631104:A:T	W111R	0.999
15:78631182:A:G	W85R	0.999
15:78631182:A:T	W85R	0.999
15:78629704:A:G	W201R	0.998
15:78629704:A:T	W201R	0.998
15:78629793:A:G	F171S	0.998
15:78631102:C:A	W111C	0.998
15:78631102:C:G	W111C	0.998
15:78631159:C:A	W92C	0.998
15:78631159:C:G	W92C	0.998
15:78631180:C:A	W85C	0.998
15:78631180:C:G	W85C	0.998
15:78629617:G:T	R230S	0.997
15:78629790:C:G	R172P	0.997
15:78629799:A:G	L169P	0.997
15:78629852:G:C	S151R	0.997
15:78629852:G:T	S151R	0.997
15:78629854:T:G	S151R	0.997
15:78631161:A:G	W92R	0.997
15:78631161:A:T	W92R	0.997
15:78631166:A:G	L90P	0.997
15:78629804:G:C	C167W	0.996
15:78629866:C:G	A147P	0.996
15:78629889:C:A	G139V	0.996
15:78629901:A:T	V135D	0.996
15:78631097:G:T	P113H	0.996
15:78631176:C:G	D87H	0.996

dbSNP variants (sampled 300 via entrez): RS1000166231 (15:78650209 A>G), RS1000219662 (15:78634982 G>T), RS1000253384 (15:78638577 G>A), RS1000268528 (15:78656282 A>G), RS1000270355 (15:78635268 A>C), RS1000301146 (15:78656524 C>T), RS1000431036 (15:78661635 C>G,T), RS1000550482 (15:78636292 G>A,C), RS1000603007 (15:78636706 C>A), RS1000699238 (15:78624159 C>G,T), RS1000825099 (15:78634055 T>C), RS1000855837 (15:78661697 CCA>C), RS1000855914 (15:78662103 C>A), RS1001021909 (15:78628566 G>C), RS1001074098 (15:78653062 A>C,G,T)

Disease associations

OMIM: gene MIM:118509 | disease phenotypes: MIM:606963

GenCC curated gene-disease

Disease	Classification	Inheritance
lung cancer	Limited	Autosomal dominant

Mondo (5): frontotemporal dementia (MONDO:0017276), lung adenocarcinoma (MONDO:0005061), chronic obstructive pulmonary disease (MONDO:0005002), amyotrophic lateral sclerosis (MONDO:0004976), lung cancer (MONDO:0008903)

Orphanet (3): Frontotemporal dementia (Orphanet:282), Amyotrophic lateral sclerosis (Orphanet:803), NON RARE IN EUROPE: Adenocarcinoma of the lung (Orphanet:415268)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0007354	Amyotrophic lateral sclerosis

GWAS associations

65 associations (top):

Study	Trait	p-value
GCST000170_1	Lung cancer	5.000000e-20
GCST000171_1	Nicotine dependence	6.000000e-20
GCST000233_1	Lung cancer	1.000000e-08
GCST001102_3	Sudden cardiac arrest	4.000000e-07
GCST002539_77	Schizophrenia	2.000000e-13
GCST002584_1	Exhaled carbon monoxide levels	2.000000e-09
GCST003025_22	Attention function in attention deficit hyperactive disorder	6.000000e-06
GCST003185_2	Nicotine dependence	4.000000e-17
GCST003262_17	Post bronchodilator FEV1	4.000000e-09
GCST003262_22	Post bronchodilator FEV1	7.000000e-07
GCST003262_229	Post bronchodilator FEV1	3.000000e-13
GCST003262_407	Post bronchodilator FEV1	2.000000e-11
GCST003262_409	Post bronchodilator FEV1	1.000000e-10
GCST003262_51	Post bronchodilator FEV1	7.000000e-09
GCST003262_673	Post bronchodilator FEV1	8.000000e-09
GCST003262_739	Post bronchodilator FEV1	6.000000e-08
GCST003262_743	Post bronchodilator FEV1	2.000000e-07
GCST003262_757	Post bronchodilator FEV1	7.000000e-08
GCST003262_772	Post bronchodilator FEV1	4.000000e-13
GCST003262_800	Post bronchodilator FEV1	5.000000e-09
GCST003262_822	Post bronchodilator FEV1	3.000000e-10
GCST003262_916	Post bronchodilator FEV1	2.000000e-14
GCST003262_919	Post bronchodilator FEV1	2.000000e-08
GCST003262_957	Post bronchodilator FEV1	3.000000e-09
GCST003262_975	Post bronchodilator FEV1	1.000000e-07
GCST003264_1111	Post bronchodilator FEV1/FVC ratio	9.000000e-08
GCST003264_1115	Post bronchodilator FEV1/FVC ratio	2.000000e-07
GCST003264_1152	Post bronchodilator FEV1/FVC ratio	3.000000e-09
GCST003264_1235	Post bronchodilator FEV1/FVC ratio	1.000000e-07
GCST003264_1307	Post bronchodilator FEV1/FVC ratio	8.000000e-14

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004278	sudden cardiac arrest
EFO:0004318	smoking behavior
EFO:0006520	carbon monoxide exhalation measurement
EFO:0007636	attention function measurement
EFO:0004314	forced expiratory volume
EFO:0004713	FEV/FVC ratio
EFO:0004340	body mass index
EFO:0009369	diffusing capacity of the lung for carbon monoxide
EFO:0007874	gut microbiome measurement
EFO:0006527	smoking status measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D000690	Amyotrophic Lateral Sclerosis	C10.228.854.139; C10.574.562.250; C10.574.950.050; C10.668.467.250; C18.452.845.800.050
D057180	Frontotemporal Dementia	C10.228.140.380.266.299; C10.574.950.300.299; C18.452.845.800.300.299; F03.615.400.380.299
D029424	Pulmonary Disease, Chronic Obstructive	C08.381.495.389; C23.550.291.500.875

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (11): CHEMBL1907591 (PROTEIN COMPLEX), CHEMBL1907594 (PROTEIN COMPLEX), CHEMBL2109230 (PROTEIN COMPLEX), CHEMBL2111384 (PROTEIN COMPLEX GROUP), CHEMBL2221346 (PROTEIN COMPLEX GROUP), CHEMBL3038459 (PROTEIN COMPLEX), CHEMBL3137273 (PROTEIN COMPLEX), CHEMBL3137285 (PROTEIN COMPLEX), CHEMBL3885595 (PROTEIN COMPLEX), CHEMBL4524133 (PROTEIN COMPLEX GROUP)

Molecules with ChEMBL bioactivity

20 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 426,191 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1076903	VARENICLINE	4	5,807
CHEMBL3	NICOTINE	4	184,969
CHEMBL894	BUPROPION	4	36,982
CHEMBL267936	MECAMYLAMINE	4	5,623
CHEMBL46	ONDANSETRON	4	41,386
CHEMBL56564	TROPISETRON	4	19,312
CHEMBL667	ACETYLCHOLINE	4	124,626
CHEMBL2103881	DEXMECAMYLAMINE	3	18
CHEMBL497939	CYTISINICLINE	3	2,766
CHEMBL111659	ALTINICLINE	2	129
CHEMBL1172928	RADAFAXINE	2	1,079
CHEMBL1230982	ANABASEINE	2	139
CHEMBL1257065	STILONIUM IODIDE	2	751
CHEMBL132966	RIVANICLINE	2	911
CHEMBL134713	GTS-21	2	269
CHEMBL2179529	AZD1446	2	78
CHEMBL238465	SOFINICLINE	2	153
CHEMBL430497	TEBANICLINE	2	1,155
CHEMBL607048	18-METHOXYCORONARIDINE	2	6
CHEMBL504652	TC-2216	1	32

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

5 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10851907	Metabolism/PK	3	cotinine	Tobacco Use Disorder
rs1948	Toxicity	3	nicotine	Tobacco Use Disorder
rs2869950	Toxicity	3	nicotine	Tobacco Use Disorder
rs3813567	Toxicity	3	nicotine	Tobacco Use Disorder
rs7178270	Toxicity	3	nicotine	Tobacco Use Disorder

PharmGKB variants

6 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3813567	CHRNB4	3	2.00	1	nicotine
rs10851907	CHRNB4	3	0.00	1	cotinine
rs2869950	CHRNB4, FAM13A	3	0.00	1	nicotine
rs1948	CHRNB4	3	3.00	1	nicotine
rs7178270	CHRNB4	3	3.00	1	nicotine
rs950776	CHRNB4		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: lgic — Nicotinic acetylcholine receptors (nACh)

Binding affinities (BindingDB)

7 measured of 9 human assays (10 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL4453542	KI	2.5 nM
CHEMBL4450133	KI	6.7 nM
CHEMBL4440403	KI	20 nM
CHEMBL4535466	KI	138 nM
CHEMBL4463888	KI	631 nM
18-methoxycoronaridine	KI	700 nM
CHEMBL4468230	KI	1630 nM

ChEMBL bioactivities

1230 potent at pChembl≥5 of 1586 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.14	Ki	0.072	nM	EPIBATIDINE
10.04	Ki	0.091	nM	EPIBATIDINE
9.90	Ki	0.126	nM	CHEMBL1209244
9.83	Ki	0.149	nM	CHEMBL1209243
9.82	Ki	0.15	nM	EPIBATIDINE
9.82	Ki	0.15	nM	(-)-EPIBATIDINE
9.80	Ki	0.16	nM	CHEMBL220476
9.80	IC50	0.16	nM	CHEMBL1269126
9.80	Ki	0.158	nM	CHEMBL1209187
9.80	EC50	0.16	nM	CHEMBL1209244
9.73	Ki	0.186	nM	CHEMBL1209124
9.72	Ki	0.191	nM	EPIBATIDINE
9.70	Ki	0.2	nM	CHEMBL462846
9.70	IC50	0.2	nM	CHEMBL4869892
9.66	Ki	0.22	nM	EPIBATIDINE
9.64	Ki	0.23	nM	EPIBATIDINE
9.62	IC50	0.24	nM	CHEMBL4860756
9.61	Ki	0.243	nM	CHEMBL1209187
9.55	IC50	0.28	nM	CHEMBL4876825
9.52	Kd	0.3	nM	EPIBATIDINE
9.52	IC50	0.3	nM	CHEMBL412032
9.52	Kd	0.3	nM	(-)-EPIBATIDINE
9.46	IC50	0.35	nM	CHEMBL4462550
9.43	IC50	0.37	nM	CHEMBL4454232
9.42	Ki	0.382	nM	CHEMBL1209186
9.39	IC50	0.41	nM	CHEMBL4878931
9.34	IC50	0.46	nM	CHEMBL4556075
9.34	Ki	0.457	nM	EPIBATIDINE
9.29	IC50	0.51	nM	CHEMBL566208
9.28	Ki	0.527	nM	HOMOEPIBATIDINE
9.26	IC50	0.55	nM	CHEMBL4443845
9.24	IC50	0.57	nM	CHEMBL4585225
9.24	IC50	0.58	nM	CHEMBL566886
9.21	IC50	0.62	nM	CHEMBL566050
9.19	IC50	0.65	nM	CHEMBL4463134
9.19	IC50	0.65	nM	CHEMBL565844
9.16	Ki	0.684	nM	CHEMBL4163848
9.15	IC50	0.7	nM	CHEMBL569465
9.13	Ki	0.748	nM	CHEMBL1209124
9.12	IC50	0.75	nM	CHEMBL429557
9.10	Ki	0.799	nM	CHEMBL4170527
9.09	Ki	0.818	nM	CHEMBL4163257
9.07	Ki	0.856	nM	CHEMBL1209126
9.05	Ki	0.882	nM	CHEMBL1209072
9.04	IC50	0.92	nM	CHEMBL4531333
9.03	Ki	0.944	nM	CHEMBL363973
9.03	Ki	0.925	nM	HOMOEPIBATIDINE
9.03	IC50	0.93	nM	CHEMBL425006
9.02	IC50	0.95	nM	CHEMBL4440025
9.02	Ki	0.957	nM	CHEMBL1209184

PubChem BioAssay actives

1157 with measured affinity, of 2985 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0001	uM
N-[5-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]-3-pyridinyl]ethanesulfonamide;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0001	uM
N-[5-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]-3-pyridinyl]propane-2-sulfonamide;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0001	uM
(1R,2R,4S)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	1563867: Displacement of [3H]epibatidine from human alpha3beta4 nAChR transfected in HEK243 cell membrane	ki	0.0001	uM
3-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-24-(3-carbamimidamidopropyl)-6-carbamoyl-48-(hydroxymethyl)-21,30,45-tris(1H-imidazol-5-ylmethyl)-9-(2-methylpropyl)-8,11,14,20,23,26,29,32,35,38,44,47,50,52-tetradecaoxo-27,36-di(propan-2-yl)-3,4,55,56-tetrathia-7,10,13,19,22,25,28,31,34,37,43,46,49,51-tetradecazatetracyclo[31.17.7.015,19.039,43]heptapentacontan-12-yl]propanoic acid	1753051: Inhibition of human alpha6/alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current response measured after 5 min by two-electrode voltage-clamp method	ic50	0.0002	uM
3-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-24,30-bis(2-amino-2-oxoethyl)-9-[(2S)-butan-2-yl]-6-carbamoyl-48-(hydroxymethyl)-21,45-bis(1H-imidazol-5-ylmethyl)-8,11,14,20,23,26,29,32,35,38,44,47,50,52-tetradecaoxo-27,36-di(propan-2-yl)-3,4,55,56-tetrathia-7,10,13,19,22,25,28,31,34,37,43,46,49,51-tetradecazatetracyclo[31.17.7.015,19.039,43]heptapentacontan-12-yl]propanoic acid	1753051: Inhibition of human alpha6/alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current response measured after 5 min by two-electrode voltage-clamp method	ic50	0.0002	uM
7-(6-chloro-3-pyridinyl)-2-azabicyclo[2.2.1]heptane	276250: Displacement of [3H]epibatidine from human recombinant alpha-3-beta-4 nAChR in HEK293 cells by SPA assay	ki	0.0002	uM
3-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.1.1]heptane	1252850: Displacement of [3H]-Epibatidine from human aplha3beta4 nAChR expressed in HEK293 cells pre-incubated for 5 mins followed by overnight incubation by radioligand liquid scintillation counter analysis	ki	0.0002	uM
(2S)-N-[3-[4-(3-aminopropylamino)butylamino]propyl]-3-cyclohexyl-2-[(2-naphthalen-1-ylacetyl)amino]propanamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0002	uM
5-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]pyridin-3-ol;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0002	uM
N-[5-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]-3-pyridinyl]methanesulfonamide;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0002	uM
(2S)-N-[3-[4-(3-aminopropylamino)butylamino]propyl]-3-cyclohexyl-2-[[(E)-3-phenylprop-2-enoyl]amino]propanamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0003	uM
3-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-30-(2-amino-2-oxoethyl)-24-(3-carbamimidamidopropyl)-6-carbamoyl-48-(hydroxymethyl)-21,45-bis(1H-imidazol-5-ylmethyl)-9-(2-methylpropyl)-8,11,14,20,23,26,29,32,35,38,44,47,50,52-tetradecaoxo-27,36-di(propan-2-yl)-3,4,55,56-tetrathia-7,10,13,19,22,25,28,31,34,37,43,46,49,51-tetradecazatetracyclo[31.17.7.015,19.039,43]heptapentacontan-12-yl]propanoic acid	1753051: Inhibition of human alpha6/alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current response measured after 5 min by two-electrode voltage-clamp method	ic50	0.0003	uM
(3S)-3-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid	241633: Inhibitory concentration against Nicotinic acetylcholine receptor alpha3-beta4	ic50	0.0003	uM
N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-3-cyclohexyl-1-oxopropan-2-yl]benzamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0004	uM
3-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-9-[(2S)-butan-2-yl]-24-(3-carbamimidamidopropyl)-6-carbamoyl-48-(hydroxymethyl)-21,30,45-tris(1H-imidazol-5-ylmethyl)-8,11,14,20,23,26,29,32,35,38,44,47,50,52-tetradecaoxo-27,36-di(propan-2-yl)-3,4,55,56-tetrathia-7,10,13,19,22,25,28,31,34,37,43,46,49,51-tetradecazatetracyclo[31.17.7.015,19.039,43]heptapentacontan-12-yl]propanoic acid	1753051: Inhibition of human alpha6/alpha3beta4 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-induced current response measured after 5 min by two-electrode voltage-clamp method	ic50	0.0004	uM
N-[3-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]-4-pyridinyl]methanesulfonamide;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0004	uM
N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]cyclohexanecarboxamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0005	uM
6-(6-chloro-3-pyridinyl)-8-azabicyclo[3.2.1]octane	276250: Displacement of [3H]epibatidine from human recombinant alpha-3-beta-4 nAChR in HEK293 cells by SPA assay	ki	0.0005	uM
2-(tert-butylamino)-1-(3,4-dichlorophenyl)butan-1-one	459714: Antagonist activity at alpha3beta4 nAChR receptor in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0005	uM
N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-3-cyclohexyl-1-oxopropan-2-yl]cycloheptanecarboxamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0006	uM
N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-3-cyclohexyl-1-oxopropan-2-yl]cyclopentanecarboxamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0006	uM
N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]cyclopentanecarboxamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0006	uM
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one	459714: Antagonist activity at alpha3beta4 nAChR receptor in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0006	uM
2-(tert-butylamino)-1-(3-chloro-4-methylphenyl)propan-1-one	459714: Antagonist activity at alpha3beta4 nAChR receptor in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0006	uM
2-(tert-butylamino)-1-(3,4-dichlorophenyl)pentan-1-one	459714: Antagonist activity at alpha3beta4 nAChR receptor in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0006	uM
5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-(4-nitrophenyl)pyridin-3-amine	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0007	uM
2-(tert-butylamino)-1-(3-chlorophenyl)pentan-1-one	459714: Antagonist activity at alpha3beta4 nAChR receptor in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0007	uM
5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-phenylpyridin-3-amine	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0008	uM
5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-[4-(trifluoromethyl)phenyl]pyridin-2-amine	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0008	uM
(3S)-3-[[(2S)-1-[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxo-4-[[(2R)-1-oxo-3-sulfanylpropan-2-yl]amino]butanoic acid	242203: Inhibitory concentration against Nicotinic acetylcholine receptor alpha2-beta4; Range is 0.3-1.5 nM	ic50	0.0008	uM
5-(6-chloro-3-pyridinyl)-2-azabicyclo[2.2.1]heptane	276250: Displacement of [3H]epibatidine from human recombinant alpha-3-beta-4 nAChR in HEK293 cells by SPA assay	ki	0.0009	uM
N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-1-oxo-3-phenylpropan-2-yl]butanamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0009	uM
(2S)-N-[3-[4-(3-aminopropylamino)butylamino]propyl]-2-[[2-(2-bicyclo[2.2.1]heptanyl)acetyl]amino]-3-cyclohexylpropanamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0009	uM
N-[(2S)-1-[3-[[(1R,2R)-2-[(3-aminopropylamino)methyl]cyclopropyl]methylamino]propylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]butanamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0009	uM
(1R,5R,6S)-6-[2-(4-methoxy-3-pyridinyl)phenoxy]-3-azabicyclo[3.2.1]octane;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0009	uM
(1R,5R,6S)-6-[2-(4-fluoro-3-pyridinyl)phenoxy]-3-azabicyclo[3.2.1]octane;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0009	uM
4-[[5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-3-pyridinyl]amino]phenol	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0010	uM
5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0010	uM
(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene	1973135: Displacement of [3H]Ibogaine from human alpha3beta4 nAChRs expressed in HEK293 cells assessed as inhibition constant incubated for 2 hrs by scintillation counter analysis	ki	0.0010	uM
(3S)-3-amino-4-[(2S)-2-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-4-amino-1-[(2S)-2-[[(2S)-1-[[(2R)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acid	242122: Inhibitory concentration against Nicotinic acetylcholine receptor alpha3-beta4; Range is 0.7-1 nM	ic50	0.0010	uM
3-[2-[[(1R,5R,6S)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]pyridin-4-amine;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0010	uM
N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-3-cyclohexyl-1-oxopropan-2-yl]cyclobutanecarboxamide	1563140: Antagonist activity at alpha3beta4 nAChR (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of Ach-induced channel activation at -100 mV holding potential treated for 1 min by two electrode voltage-clamp assay	ic50	0.0011	uM
N-(4-chlorophenyl)-5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-amine	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0012	uM
2-[tert-butyl(methyl)amino]-1-(3-chlorophenyl)propan-1-one	459714: Antagonist activity at alpha3beta4 nAChR receptor in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0012	uM
(1R,5R,6S)-6-(2-pyridin-3-ylphenoxy)-3-azabicyclo[3.2.1]octane;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0012	uM
5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-(4-fluorophenyl)pyridin-3-amine	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0013	uM
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one	459714: Antagonist activity at alpha3beta4 nAChR receptor in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	ic50	0.0013	uM
N-[5-[2-[[(1S,5S,6R)-3-azabicyclo[3.2.1]octan-6-yl]oxy]phenyl]-3-pyridinyl]methanesulfonamide;hydrochloride	495033: Displacement of [3H]epibatidine from alpha3beta4 nicotinic receptor expressed in human HEK293 cells	ki	0.0013	uM
5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-(4-methylphenyl)pyridin-3-amine	1359525: Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK293 cell membranes	ki	0.0014	uM

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetylcholine	decreases reaction, increases activity, affects binding, affects reaction, increases reaction (+2 more)	6
epibatidine	decreases reaction, increases activity, affects binding	3
bisphenol A	decreases methylation, affects activity, affects binding, decreases reaction, increases reaction	2
entinostat	increases expression, affects cotreatment	2
Estradiol	affects cotreatment, increases expression, affects activity, affects binding, decreases reaction (+1 more)	2
Nicotine	affects binding, increases activity	2
Tubocurarine	affects binding, decreases reaction, increases activity	2
triptolide	affects binding, decreases reaction, increases activity	1
cytisine	affects binding, increases activity	1
propionaldehyde	decreases expression	1
crotonyl alcohol	increases reaction, increases transport, affects binding, decreases reaction	1
N’-nitrosonornicotine	affects binding	1
decabromobiphenyl ether	increases expression	1
tetrabromobisphenol A	increases expression	1
n-pentanol	decreases reaction, increases reaction, increases transport, affects binding	1
coumarin	decreases phosphorylation	1
isobutyl alcohol	affects binding, affects reaction, increases reaction, increases transport	1
tetrachlorodian	increases expression	1
4-nonylphenol	decreases reaction, increases reaction, affects activity, affects binding	1
2-butanol	affects reaction, increases reaction, increases transport, affects binding	1
celastrol	increases activity, affects binding, decreases reaction	1
4-octylphenol	affects activity, affects binding, decreases reaction	1
imidacloprid	affects binding, increases activity	1
CGP 52608	affects binding, increases reaction	1
cisatracurium	affects binding, decreases reaction, increases activity	1
4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride	affects binding, increases activity	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
1,2-bis-N-cytisinylethane	affects binding, increases reaction, increases localization	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1

ChEMBL screening assays

407 unique, capped per target: 309 binding, 96 functional, 2 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1020768	Binding	Displacement of [3H]epibatidine from alpha4beta4 nAChR expressed in HEK293 cells	Carbamoylcholine analogs as nicotinic acetylcholine receptor agonists–structural modifications of 3-(dimethylamino)butyl dimethylcarbamate (DMABC). — Bioorg Med Chem Lett
CHEMBL1068091	Functional	Antagonist activity at human alpha4beta4 nAChR receptor expressed in human SH-SY5Y cells assessed as inhibition of carbamylcholine-induced 86Rb+ efflux by liquid scintillation counting	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. — J Med Chem
CHEMBL4603065	ADMET	Inhibition of human alpha3beta4 nAChR assessed as increase in acetylcholine-induced normalized current at 2 uM (Rvb = 78.5 +/- 10 uM)	Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1KF	PrecisION hnAChR alpha3/beta4-HEK	Transformed cell line	Female

Clinical trials (associated diseases)

455 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00158041	PHASE4	COMPLETED	Subcutaneous Amifostine Safety Study
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00440960	PHASE4	COMPLETED	Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic
NCT00492843	PHASE4	TERMINATED	Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT00675168	PHASE4	UNKNOWN	Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice
NCT00712647	PHASE4	COMPLETED	Carotene and Retinol Efficacy Trial
NCT00747773	PHASE4	COMPLETED	Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung
NCT01060137	PHASE4	COMPLETED	Fentanyl Matrix in Lung Cancer Pain
NCT01381627	PHASE4	UNKNOWN	Safety Evaluation of Dexmedetomidine for EBUS-TBNA
NCT01741506	PHASE4	COMPLETED	Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer
NCT02246023	PHASE4	COMPLETED	Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
NCT02275702	PHASE4	COMPLETED	Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients
NCT02346318	PHASE4	UNKNOWN	The Randomized Controlled Clinical Trial of Kushen Injection
NCT02476526	PHASE4	COMPLETED	Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
NCT02490059	PHASE4	COMPLETED	Ultrathin Bronchoscopy for Solitary Pulmonary Nodules
NCT02504801	PHASE4	UNKNOWN	Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD
NCT02869789	PHASE4	COMPLETED	An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT03302221	PHASE4	WITHDRAWN	Regional Haemodynamic Changes in Radial Artery Assessment With Continuous Pulsed-wave Doppler Ultrasound
NCT03313544	PHASE4	UNKNOWN	Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
NCT03394222	PHASE4	COMPLETED	Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV
NCT03570645	PHASE4	COMPLETED	Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block
NCT03571126	PHASE4	UNKNOWN	Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
NCT03642457	PHASE4	TERMINATED	Efficacy Between Serratus Plane Block And Local Infiltration In Vats
NCT04145570	PHASE4	COMPLETED	A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
NCT04155008	PHASE4	TERMINATED	Nutrition and Pharmacological Algorithm for Oncology Patients Study
NCT04613284	PHASE4	UNKNOWN	Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC
NCT05463913	PHASE4	RECRUITING	Lung Nodule Detection Using Ultra-long FOV PET/CT
NCT05521789	PHASE4	RECRUITING	Erector Spinae Block for Thoracic Surgery
NCT05525338	PHASE4	RECRUITING	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
NCT05663242	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06105801	PHASE4	RECRUITING	EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
NCT06276933	PHASE4	NOT_YET_RECRUITING	A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06646471	PHASE4	RECRUITING	PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
NCT07405086	PHASE4	RECRUITING	Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
NCT00376051	PHASE4	COMPLETED	Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
NCT00950430	PHASE4	ENROLLING_BY_INVITATION	Imaging of Brain Amyloid Plaques in the Aging Population
NCT06093126	PHASE4	RECRUITING	Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial